Daniel Pollyea, MD
Enriched profileProfessor of Medicine; Clinical Director of Leukemia Services; Robert H. Allen MD Endowed Chair in Hematology Research; Interim Chief, Division of Hematology, Department of Medicine, University of Colorado School of Medicine · University of Colorado School of Medicine
Daniel Pollyea is Professor of Medicine; Clinical Director of Leukemia Services; Robert H. Allen MD Endowed Chair in Hematology Research; Interim Chief, Division of Hematology, Department of Medicine, University of Colorado School of Medicine at University of Colorado School of Medicine. OpenAlex indexes 558 publications with 25,464 citations (h-index 70); ClinicalTrials.gov lists 10 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Daniel A. Pollyea, MD, is Professor of Medicine at University of Colorado School of Medicine / University of Colorado Cancer Center (Aurora, CO). The public record shows 558 publications with 25,464 citations (h-index 70), centered on Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Acute Lymphoblastic Leukemia research. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 24 companies, 2 NIH-funded awards (2024–2026).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Acute Myeloid Leukemia Research
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 24 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 37 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 173.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)
Sponsor: University of Colorado, Denver
- Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
Sponsor: University of Colorado, Denver
- KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia
Sponsor: University of Colorado, Denver
Industry payments
Updated 14 Oct 2026
24 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- SERVIER PHARMACEUTICALS LLCProgram year20258 payments
- ABBVIE INC.Program year20259 payments
- Geron CorporationProgram year20256 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
58.4%Kinase inhibitor29.4%Tasigna40%Sprycel28%Imatinib Mesylate21%Imbruvica12%Part D<11 patientsBCL-2 Inhibitor12.2%Venclexta100%Part D≥13 patients+ 3 more classes in this area
Dermatology
14.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor14.2%Acyclovir100%Part D≥16 patientsMetabolism & gastrointestinal
13.7%Serotonin-3 Receptor Antagonist10.5%Ondansetron Hcl61%Granisetron Hcl39%Part D<11 patientsPotassium supplement3.2%Potassium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
2 NIH research awards on record, funded 2024–2026 per NIH RePORTER. The latest:
- Targeting mitochondrial calcium to eradicate leukemia-initiating cells
University of Colorado Denver
FY2026$1,312,295R01CA292071 - IAP inhibition as a therapeutic strategy to target therapy-resistant leukemia initiating cells
University of Colorado Denver
FY2026$387,630R01CA292432 - Targeting mitochondrial calcium to eradicate leukemia-initiating cells
University of Colorado Denver
FY2025$437,432R01CA292071
Congress activity
Updated 14 Oct 2026
128 congress contributions (2010–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Real-world patient management practices in responders to venetoclax for newly diagnosed acute myeloid leukemia.
ASCO Annual Meeting
ASCO2025Co-author - Tolerability and outcomes with serial cycles of 28 days of venetoclax in newly diagnosed patients with AML.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.
Journal of clinical oncology
Article2026 - RAS pathway activation and microenvironmental adaptation as hallmarks of myeloid sarcoma.
Blood cancer discovery
Article2026 - Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia.
American journal of hematology
Article2026 - Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study.
Blood cancer discovery
Article2025
Most-cited works
by citation count (OpenAlex)- 01
- 02Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia1,474 citations2017
- 03Functional genomic landscape of acute myeloid leukaemia1,462 citations2018
- 04
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- ResearchGate
researchgate.net/profile/Daniel-Pollyea
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/thomas-flaig-md-cuanschutz_daniel-pollyea-md-ms-recognized-by-the-activity-7292269690268041216-2Tgd
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - X / Twitter
X (Twitter) account @DanPollyea
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- National Comprehensive Cancer Network (NCCN)
AML Guidelines Committee, Member (2013–present), Vice-Chairman (2019–2021), Chairman
2021verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- Leukemia and Lymphoma Society of Canada
Scientific Advisory Board
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗ - Acute Leukemia Forum Annual Meeting
Co-Chairman
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.cuanschutz.edu ↗
Secondary affiliations
appointments beyond the home institution- University of Colorado Hospital / UCHealth Blood Disorders and Cell Therapies Center
affiliated hospital / clinical practice site
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cumedicine.us ↗ - American Society of Hematology
professional membership
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗ - American Society of Clinical Oncology
professional membership
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
- Research To Practice video podcast series
Daniel A. Pollyea, MD, MS on Acute Myeloid Leukemia
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →videopodcast.researchtopractice.com ↗ - The Hematology Podcast Series
recurring guest discussing AML classification and trial data (e.g., ELN classification episode with Dr. Brian Leber)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancernetwork.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Abman, MD
University of Colorado School of Medicine
Nanette Santoro, MD
University of Colorado School of Medicine
Ronald Sokol, MD
University of Colorado School of Medicine
Michael Verneris, MD
University of Colorado School of Medicine
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center